Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab Tirumotecan plus Iparomlimab and Tuvonralimab in Locally Advanced Cervical Cancer
NCT07348861Phase 2Not yet recruiting
- Sponsor
- Zhengzhou Minzhong Pharmaceutical
- Start
- Feb 2026
- Primary completion
- Jan 2028
- Modality
- Immune Checkpoint Inhibitors, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sacituzumab tirumotecan, iparomlimab and tuvonralimab in Cervical Cancer (CC), sponsored by Zhengzhou Minzhong Pharmaceutical. Primary endpoint: Pathological Complete Response Rate at 8 weeks. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
sacituzumab tirumotecaniparomlimabtuvonralimab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT07348861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07348861.